Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ursula Ravens has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The right atrium affects in silico arrhythmia vulnerability in both atria

    by P Martinez Diaz, J Sanchez, N A Fitzen, U Ravens, O Doessel, A Loewe

    Introduction: The role of the right atrium (RA) in atrial fibrillation (AF) has long been overlooked. Computer models of the atria can aid in assessing how the RA influences arrhythmia vulnerability and in studying the role of RA drivers in the induction of AF, both aspects challenging to assess in living patients. It remains unclear if incorporating the RA influences the reentry inducibility of the model. As personalized ablation strategies rely on non-inducibility criteria, the adequacy of left atrium (LA)-only models for developing such ablation tools is uncertain. Aim: To evaluate the effect of incorporating the RA in 3D patient-specific computer models on arrhythmia vulnerability. Methods: Imaging data from 8 subjects were obtained to generate patient-specific computer models. We created 2 models for each subject: a monoatrial with only the LA and a biatrial with both the RA and LA. We considered 3 different states of substrate remodeling: healthy (H), mild (M), and severe (S). The Courtemanche cellular model was modified from control conditions to a setup representing AF-induced remodeling [1] with 0%, 50%, and 100% changes for H, M, and S, respectively. Conduction velocity was set to 1.2, 1.0, and 0.8m/s for each remodeling state. Fibrosis extent corresponded to Utah 2 (5-20%) and Utah 4 (>35%) stages [2] for M and S, while the H state was modeled without fibrosis. Arrhythmia vulnerability was assessed by virtual S1S2 pacing from different points separated by 2cm using openCARP [3]. A point was classified as inducing arrhythmia if reentry was maintained for at least 1s. The vulnerability ratio was defined as the number of inducing points divided by the number of stimulation points. The mean tachycardia cycle length (TCL) was assessed at the stimulation site. We compared LA vulnerability ratios in monoatrial and biatrial models. Results: Incorporating the RA increased the mean LA vulnerability ratio by 115.8% (0.19±0.13 to 0.41±0.22, p=0.033) in state M and 29.0% in state S (0.31±0.14 to 0.40±0.15, p=0.219) as illustrated in Figure 1. No arrhythmia was induced in the H models. RA inclusion increased the TCL of LA reentries by 5.5% (186.9±13.3ms to 197.2±18.3ms, p=0.006) in scenario M and decreased it by 7.2% (224.3±27.6ms to 208.2±34.8ms, p=0.010) in scenario S. RA inclusion increased LA inducibility revealing 5.5±3.0 new points per patient in the LA for the biatrial model, which did not induce reentry in the monoatrial model. Conclusions: LA arrhythmia vulnerability in a biatrial model differs from that in a monoatrial model. Incorporating the RA in patient-specific computational models unmasked potential inducing points in the LA. The RA had a substrate-dependent effect on reentry dynamics, altering the TCL of LA-induced reentries. Our results provide evidence for an important role of the RA in the maintenance and induction of arrhythmia in patient-specific computational models, thus suggesting the use of biatrial models.


  • Open Access

    Piezo1 Channels Contribute to the Regulation of Human Atrial Fibroblast Mechanical Properties and Matrix Stiffness Sensing

    by Ramona Emig, Wiebke Knodt, Mario J. Krussig, Callum M. Zgierski-Johnston, Oliver Gorka, Olaf Groß, Peter Kohl, Ursula Ravens, Rémi Peyronnet

    The mechanical environment of cardiac cells changes continuously and undergoes major alterations during diseases. Most cardiac diseases, including atrial fibrillation, are accompanied by fibrosis which can impair both electrical and mechanical function of the heart. A key characteristic of fibrotic tissue is excessive accumulation of extracellular matrix, leading to increased tissue stiffness. Cells are known to respond to changes in their mechanical environment, but the molecular mechanisms underlying this ability are incompletely understood. We used cell culture systems and hydrogels with tunable stiffness, combined with advanced biophysical and imaging techniques, to elucidate the roles of the stretch-activated channel Piezo1 in human atrial fibroblast mechano-sensing. Changing the expression level of Piezo1 revealed that this mechano-sensor contributes to the organization of the cytoskeleton, affecting mechanical properties of human embryonic kidney cells and human atrial fibroblasts. Our results suggest that this response is independent of Piezo1-mediated ion conduction at the plasma membrane, and mediated in part by components of the integrin pathway. Further, we show that Piezo1 is instrumental for fibroblast adaptation to changes in matrix stiffness, and that Piezo1-induced cell stiffening is transmitted in a paracrine manner to other cells by a signaling mechanism requiring interleukin-6. Piezo1 may be a new candidate for targeted interference with cardiac fibroblast function.


  • Block of Na + /Ca 2+ exchanger by SEA0400 in human right atrial preparations from patients in sinus rhythm and in atrial fibrillation

    by Torsten Christ, Peter P. Kovács, Karoly Acsai, Michael Knaut, Thomas Eschenhagen, Norbert Jost, András Varró, Erich Wettwer, Ursula Ravens


  • Open Access

    Late Sodium Current in Human Atrial Cardiomyocytes from Patients in Sinus Rhythm and Atrial Fibrillation

    by Claire Poulet, Erich Wettwer, Morten Grunnet, Thomas Jespersen, Larissa Fabritz, Klaus Matschke, Michael Knaut, Ursula Ravens

    Slowly inactivating Na+ channels conducting “late” Na+ current (INa,late) contribute to ventricular arrhythmogenesis under pathological conditions. INa,late was also reported to play a role in chronic atrial fibrillation (AF). The objective of this study was to investigate INa,late in human right atrial cardiomyocytes as a putative drug target for treatment of AF. To activate Na+ channels, cardiomyocytes from transgenic mice which exhibit INa,late (ΔKPQ), and right atrial cardiomyocytes from patients in sinus rhythm (SR) and AF were voltage clamped at room temperature by 250-ms long test pulses to -30 mV from a holding potential of -80 mV with a 100-ms pre-pulse to -110 mV (protocol I). INa,late at -30 mV was not discernible as deviation from the extrapolated straight line IV-curve between -110 mV and -80 mV in human atrial cells. Therefore, tetrodotoxin (TTX, 10 μM) was used to define persistent inward current after 250 ms at -30 mV as INa,late. TTX-sensitive current was 0.27±0.06 pA/pF in ventricular cardiomyocytes from ΔKPQ mice, and amounted to 0.04±0.01 pA/pF and 0.09±0.02 pA/pF in SR and AF human atrial cardiomyocytes, respectively. With protocol II (holding potential -120 mV, pre-pulse to -80 mV) TTX-sensitive INa,late was always larger than with protocol I. Ranolazine (30 μM) reduced INa,late by 0.02±0.02 pA/pF in SR and 0.09±0.02 pA/pF in AF cells. At physiological temperature (37°C), however, INa,late became insignificant. Plateau phase and upstroke velocity of action potentials (APs) recorded with sharp microelectrodes in intact human trabeculae were more sensitive to ranolazine in AF than in SR preparations. Sodium channel subunits expression measured with qPCR was high for SCN5A with no difference between SR and AF. Expression of SCN8A and SCN10A was low in general, and lower in AF than in SR. In conclusion, We confirm for the first time a TTX-sensitive current (INa,late) in right atrial cardiomyocytes from SR and AF patients at room temperature, but not at physiological temperature. While our study provides evidence for the presence of INa,late in human atria, the potential of such current as a target for the treatment of AF remains to be demonstrated.


  • Open Access

    Atrial selectivity of antiarrhythmic drugs

    by Ursula Ravens, Claire Poulet, Erich Wettwer, Michael Knaut

    Abstract  New antiarrhythmic drugs for treatment of atrial fibrillation should ideally be atrial selective in order to avoid pro‐arrhythmic effects in the ventricles. Currently recognized atrial selective targets include atrial Nav1.5 channels, Kv1.5 channels and constitutively active Kir3.1/3.4 channels, each of which confers atrial selectivity by different mechanisms. Na+ channel blockers with potential‐ and frequency‐dependent action preferentially suppress atrial fibrillation because of the high excitation rate and less negative atrial resting potential, which promote drug binding in atria. Kv1.5 channels are truly atrial selective because they do not conduct repolarizing current IKur in ventricles. Constitutively active IK,ACh is predominantly observed in remodelled atria from patients in permanent atrial fibrillation (AF). A lot of effort has been invested to detect compounds which will selectively block Kir3.1/Kir3.4 in their remodelled constitutively active form. Novel drugs which have been and are being developed aim at atrial‐selective targets. Vernakalant and ranolazine which mainly block atrial Na+ channels are clinically effective. Newly designed selective IKur blockers and IK,ACh blockers are effective in animal models; however, clinical benefit in converting AF into sinus rhythm (SR) or reducing AF burden remains to be demonstrated. In conclusion, atrial‐selective antiarrhythmic agents have a lot of potential, but a long way to go.